178 related articles for article (PubMed ID: 14500473)
1. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom.
Borrow R; Goldblatt D; Finn A; Southern J; Ashton L; Andrews N; Lal G; Riley C; Rahim R; Cartwright K; Allan G; Miller E
Infect Immun; 2003 Oct; 71(10):5549-55. PubMed ID: 14500473
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains.
Richmond P; Borrow R; Findlow J; Martin S; Thornton C; Cartwright K; Miller E
Infect Immun; 2001 Apr; 69(4):2378-82. PubMed ID: 11254596
[TBL] [Abstract][Full Text] [Related]
3. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.
Pace D; Khatami A; McKenna J; Campbell D; Attard-Montalto S; Birks J; Voysey M; White C; Finn A; Macloed E; Faust SN; Kent AL; Heath PT; Borrow R; Snape MD; Pollard AJ
BMJ; 2015 Apr; 350():h1554. PubMed ID: 25832102
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers.
Nolan T; Booy R; Marshall HS; Richmond P; Nissen M; Ziegler JB; Baine Y; Traskine M; Jastorff A; Van der Wielen M
Pediatr Infect Dis J; 2019 Jun; 38(6):643-650. PubMed ID: 31116180
[TBL] [Abstract][Full Text] [Related]
6. Single priming dose of meningococcal group C conjugate vaccine (NeisVac-C®) in infants.
Poellabauer EM; Pavlova BG; Fritsch S; Singer J; Neubauer C; Doralt J; Valenta-Singer B; Ehrlich HJ
Vaccine; 2013 Aug; 31(35):3611-6. PubMed ID: 23672977
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United kingdom.
Findlow H; Borrow R; Andrews N; Waight P; Sheasby E; Matheson M; England A; Goldblatt D; Ashton L; Findlow J; Miller E
Pediatr Infect Dis J; 2012 Jun; 31(6):616-22. PubMed ID: 22333698
[TBL] [Abstract][Full Text] [Related]
8. Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy.
Pace D; Khatami A; Attard-Montalto S; Voysey M; Finn A; Faust SN; Heath PT; Borrow R; Snape MD; Pollard AJ
Vaccine; 2016 Dec; 34(50):6350-6357. PubMed ID: 28029540
[TBL] [Abstract][Full Text] [Related]
9. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age.
Habermehl P; Leroux-Roels G; Sänger R; Mächler G; Boutriau D
Hum Vaccin; 2010 Aug; 6(8):640-51. PubMed ID: 20697200
[TBL] [Abstract][Full Text] [Related]
10. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D
Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785
[TBL] [Abstract][Full Text] [Related]
11. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom.
Southern J; Borrow R; Andrews N; Morris R; Waight P; Hudson M; Balmer P; Findlow H; Findlow J; Miller E
Clin Vaccine Immunol; 2009 Feb; 16(2):194-9. PubMed ID: 19091990
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial.
Davis K; Valente Pinto M; Andrews NJ; Goldblatt D; Borrow R; Findlow H; Southern J; Partington J; Plested E; Patel S; Holland A; Matheson M; England A; Hallis B; Miller E; Snape MD
Lancet Infect Dis; 2021 May; 21(5):688-696. PubMed ID: 33428870
[TBL] [Abstract][Full Text] [Related]
14. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.
Richmond P; Borrow R; Goldblatt D; Findlow J; Martin S; Morris R; Cartwright K; Miller E
J Infect Dis; 2001 Jan; 183(1):160-3. PubMed ID: 11078484
[TBL] [Abstract][Full Text] [Related]
15. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D;
Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
[TBL] [Abstract][Full Text] [Related]
18. Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children.
Knuf M; Baine Y; Bianco V; Boutriau D; Miller JM
Hum Vaccin Immunother; 2012 Jul; 8(7):866-72. PubMed ID: 22485049
[TBL] [Abstract][Full Text] [Related]
19. Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination.
van Ravenhorst MB; Marinovic AB; van der Klis FR; van Rooijen DM; van Maurik M; Stoof SP; Sanders EA; Berbers GA
Vaccine; 2016 Dec; 34(50):6309-6315. PubMed ID: 27817957
[TBL] [Abstract][Full Text] [Related]
20. Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule.
Ladhani SN; Andrews NJ; Waight P; Hallis B; Matheson M; England A; Findlow H; Bai X; Borrow R; Burbidge P; Pearce E; Goldblatt D; Miller E
Vaccine; 2015 Jan; 33(5):648-55. PubMed ID: 25510388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
